title: Orlistat, a novel potent antitumor agent for ovarian cancer: proteomic             analysis of ovarian cancer cells treated with Orlistat.
abstract: Orlistat is an orally administered anti-obesity drug that has shown significant             antitumor activity in a variety of tumor cells. To identify the proteins involved             in its antitumor activity, we employed a proteomic approach to reveal protein             expression changes in the human ovarian cancer cell line SKOV3, following Orlistat             treatment. Protein expression profiles were analyzed by 2-dimensional polyacrylamide             gel electrophoresis (2-DE) and protein identification was performed on a MALDI-Q-TOF             MS/MS instrument. More than 110 differentially expressed proteins were visualized             by 2-DE and Coomassie brilliant blue staining. Furthermore, 71 proteins differentially             expressed proteins were positively identified via mass spectrometry (MS)/MS analysis.             In particular, PKM1/2, a key enzyme involved in tumorigenesis, was found to be             significantly downregulated in SKOV3 cells following treatment with Orlistat.             Moreover, PKM1/2 was proved to be downregulated in SKOV3 cells by western blot             analysis after treatment with Orlistat. Taken together, using proteomic tools,             we identified several differentially expressed proteins that underwent Orlistat-induced             apoptosis, particularly PKM2. These changes confirmed our hypothesis that Orlistat             is a potential inhibitor of ovarian cancer and can be used as a novel adjuvant             antitumor agent.
authors.affiliation: Department of Gynecology and Obstetrics, Sichuan University, Chengdu, Sichuan, People's Republic of China.
authors.forename: Hui-Qiong
authors.initials: HQ
authors.lastname: Huang
authors.forename: Jing
authors.initials: J
authors.lastname: Tang
authors.forename: Sheng-Tao
authors.initials: ST
authors.lastname: Zhou
authors.forename: Tao
authors.initials: T
authors.lastname: Yi
authors.forename: Hong-Ling
authors.initials: HL
authors.lastname: Peng
authors.forename: Guo-Bo
authors.initials: GB
authors.lastname: Shen
authors.forename: Na
authors.initials: N
authors.lastname: Xie
authors.forename: Kai
authors.initials: K
authors.lastname: Huang
authors.forename: Tao
authors.initials: T
authors.lastname: Yang
authors.forename: Jin-Hua
authors.initials: JH
authors.lastname: Wu
authors.forename: Can-Hua
authors.initials: CH
authors.lastname: Huang
authors.forename: Yu-Quan
authors.initials: YQ
authors.lastname: Wei
authors.forename: Xia
authors.initials: X
authors.lastname: Zhao
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D002352:Carrier Proteins / Q000378:metabolism; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D016000:Cluster Analysis; D015180:Electrophoresis, Gel, Two-Dimensional; D054890:Fatty Acid Synthase, Type I / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D007783:Lactones / Q000494:pharmacology*; D008565:Membrane Proteins / Q000378:metabolism; D000077403:Orlistat; D010051:Ovarian Neoplasms; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics; D013963:Thyroid Hormones / Q000378:metabolism; D000097810:Thyroid Hormone-Binding Proteins
chemical_list: D000970:Antineoplastic Agents; D002352:Carrier Proteins; D054890:Fatty Acid Synthase, Type I; D007783:Lactones; D008565:Membrane Proteins; D000077403:Orlistat; D020543:Proteome; D013963:Thyroid Hormones; D000097810:Thyroid Hormone-Binding Proteins; C518729:FASN protein, human